Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status
Why the study?
Does combination therapy with ACE inhibitors and ARBs improve outcomes compared to monotherapy in patients with cardiovascular diseases?
Population
Patients with cardiovascular diseases, including hypertension, acute myocardial infarction, chronic systolic…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports caution against routine ACEI/ARB combination in CV disease; leaves open targeted indications and guideline harmonization.
Structured PICO
Does combination therapy with ACE inhibitors and ARBs improve outcomes compared to monotherapy in patients with cardiovascular diseases?
P
Population
Patients with cardiovascular diseases, including hypertension, acute myocardial infarction, chronic systolic heart failure, stroke, and diabetic renal disease
I
Intervention
Renin-angiotensin-aldosterone system (RAAS) blockade (isolated ACE inhibitor or ARB use, and their combination)
This review highlights the conflicting evidence and guideline recommendations regarding the combination of ACE inhibitors and ARBs, noting increased adverse effects without clear added benefit in general cardiovascular populations.
Cite This Study
KW et al. (2010) studied this question.